Paclitaxel Injection Concentrate for Nanodispersion clinical trials
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2011
How each study uses Paclitaxel Injection Concentrate for Nanodispersion is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2011 (1)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2012 | 1 |
| 2014 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Related medicines
As reviewed, each with the page that says it.
- One of Antimitotic agents source
Studies
Open first, then newest update. How each study uses Paclitaxel Injection Concentrate for Nanodispersion is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Pharmacokinetic, Safety and Tolerability Study of SPARC1028CompletedPhase 1Sun Pharma Advanced Research Company LimitedNCT01305512Written as SPARC1028How we know
- Pharmacokinetic and Safety Study of SPARC1023 Alone and in Carboplatin CombinationCompletedPhase 1Sun Pharma Advanced Research Company LimitedNCT01304303Written as SPARC1023 IHow we know
- Bioavailability Study of SPARC1210 and Reference1210 in Subjects With Metastatic Breast CancerTerminatedPhase 1Sun Pharma Advanced Research Company LimitedNCT02136927Written as SPARC1210How we know